Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis

Stamatina Kanelli, Stephen Maxted Ansell, Thomas Matthew Habermann, David J. Inwards, Nancy Tuinstra, Thomas Elmer Witzig

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Infusion related adverse events (AE) with day 1 rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL) are common. The purpose of this study was to evaluate the AE occurring in patients with malignant B-cell lymphocytosis who received rituximab. Patients with a ≥ 3 × 109/L absolute lymphocyte count (ALC) receiving rituximab from 1998 to 1999 or participating in a phase I study of rituximab and interleukin-12 were reviewed. The AE occurring on the day of rituximab, the treatment provided (including hospitalization), and the subsequent ALC responses were recorded. Twenty-seven patients were identified; 14 had NHL, one Waldenstrom's macroglobulinemia, and 12 patients had chronic lymphocytic leukemia. The baseline median ALC was 9.58 × 109/L (mean, 49.31; range, 3.56-380.95). All patients received rituximab as an outpatient. There were only two AE ≥ grade 3. One patient was hospitalized for 1 day for IV fluids to treat an increase in creatinine that occurred with tumor lysis. A second patient developed a pulmonary syndrome five days after day 1 rituximab and required mechanical ventilation, but had no long-term lung toxicity. This study demonstrates that patients with high numbers of circulating blood B-lymphocytes can usually safely receive rituximab as outpatients. Patients who experience a rapid drop in ALC should be monitored closely for tumor lysis and the pulmonary syndrome.

Original languageEnglish (US)
Pages (from-to)1329-1337
Number of pages9
JournalLeukemia and Lymphoma
Volume42
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Lymphocytosis
B-Lymphocytes
Lymphocyte Count
Non-Hodgkin's Lymphoma
Lung
Outpatients
Tumor Lysis Syndrome
Rituximab
Waldenstrom Macroglobulinemia
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Interleukin-12
Artificial Respiration
Creatinine
Hospitalization

Keywords

  • Chronic lymphocytic leukemia
  • Non-Hodgkin's lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. / Kanelli, Stamatina; Ansell, Stephen Maxted; Habermann, Thomas Matthew; Inwards, David J.; Tuinstra, Nancy; Witzig, Thomas Elmer.

In: Leukemia and Lymphoma, Vol. 42, No. 6, 2001, p. 1329-1337.

Research output: Contribution to journalArticle

@article{97a43181db7d45a3858fbc4f8b8ec5b5,
title = "Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis",
abstract = "Infusion related adverse events (AE) with day 1 rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL) are common. The purpose of this study was to evaluate the AE occurring in patients with malignant B-cell lymphocytosis who received rituximab. Patients with a ≥ 3 × 109/L absolute lymphocyte count (ALC) receiving rituximab from 1998 to 1999 or participating in a phase I study of rituximab and interleukin-12 were reviewed. The AE occurring on the day of rituximab, the treatment provided (including hospitalization), and the subsequent ALC responses were recorded. Twenty-seven patients were identified; 14 had NHL, one Waldenstrom's macroglobulinemia, and 12 patients had chronic lymphocytic leukemia. The baseline median ALC was 9.58 × 109/L (mean, 49.31; range, 3.56-380.95). All patients received rituximab as an outpatient. There were only two AE ≥ grade 3. One patient was hospitalized for 1 day for IV fluids to treat an increase in creatinine that occurred with tumor lysis. A second patient developed a pulmonary syndrome five days after day 1 rituximab and required mechanical ventilation, but had no long-term lung toxicity. This study demonstrates that patients with high numbers of circulating blood B-lymphocytes can usually safely receive rituximab as outpatients. Patients who experience a rapid drop in ALC should be monitored closely for tumor lysis and the pulmonary syndrome.",
keywords = "Chronic lymphocytic leukemia, Non-Hodgkin's lymphoma, Rituximab",
author = "Stamatina Kanelli and Ansell, {Stephen Maxted} and Habermann, {Thomas Matthew} and Inwards, {David J.} and Nancy Tuinstra and Witzig, {Thomas Elmer}",
year = "2001",
doi = "10.1080/10428190127502",
language = "English (US)",
volume = "42",
pages = "1329--1337",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis

AU - Kanelli, Stamatina

AU - Ansell, Stephen Maxted

AU - Habermann, Thomas Matthew

AU - Inwards, David J.

AU - Tuinstra, Nancy

AU - Witzig, Thomas Elmer

PY - 2001

Y1 - 2001

N2 - Infusion related adverse events (AE) with day 1 rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL) are common. The purpose of this study was to evaluate the AE occurring in patients with malignant B-cell lymphocytosis who received rituximab. Patients with a ≥ 3 × 109/L absolute lymphocyte count (ALC) receiving rituximab from 1998 to 1999 or participating in a phase I study of rituximab and interleukin-12 were reviewed. The AE occurring on the day of rituximab, the treatment provided (including hospitalization), and the subsequent ALC responses were recorded. Twenty-seven patients were identified; 14 had NHL, one Waldenstrom's macroglobulinemia, and 12 patients had chronic lymphocytic leukemia. The baseline median ALC was 9.58 × 109/L (mean, 49.31; range, 3.56-380.95). All patients received rituximab as an outpatient. There were only two AE ≥ grade 3. One patient was hospitalized for 1 day for IV fluids to treat an increase in creatinine that occurred with tumor lysis. A second patient developed a pulmonary syndrome five days after day 1 rituximab and required mechanical ventilation, but had no long-term lung toxicity. This study demonstrates that patients with high numbers of circulating blood B-lymphocytes can usually safely receive rituximab as outpatients. Patients who experience a rapid drop in ALC should be monitored closely for tumor lysis and the pulmonary syndrome.

AB - Infusion related adverse events (AE) with day 1 rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL) are common. The purpose of this study was to evaluate the AE occurring in patients with malignant B-cell lymphocytosis who received rituximab. Patients with a ≥ 3 × 109/L absolute lymphocyte count (ALC) receiving rituximab from 1998 to 1999 or participating in a phase I study of rituximab and interleukin-12 were reviewed. The AE occurring on the day of rituximab, the treatment provided (including hospitalization), and the subsequent ALC responses were recorded. Twenty-seven patients were identified; 14 had NHL, one Waldenstrom's macroglobulinemia, and 12 patients had chronic lymphocytic leukemia. The baseline median ALC was 9.58 × 109/L (mean, 49.31; range, 3.56-380.95). All patients received rituximab as an outpatient. There were only two AE ≥ grade 3. One patient was hospitalized for 1 day for IV fluids to treat an increase in creatinine that occurred with tumor lysis. A second patient developed a pulmonary syndrome five days after day 1 rituximab and required mechanical ventilation, but had no long-term lung toxicity. This study demonstrates that patients with high numbers of circulating blood B-lymphocytes can usually safely receive rituximab as outpatients. Patients who experience a rapid drop in ALC should be monitored closely for tumor lysis and the pulmonary syndrome.

KW - Chronic lymphocytic leukemia

KW - Non-Hodgkin's lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0035697071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035697071&partnerID=8YFLogxK

U2 - 10.1080/10428190127502

DO - 10.1080/10428190127502

M3 - Article

VL - 42

SP - 1329

EP - 1337

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -